Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.
OBJECTIVE
Osteoporosis causes morbidity and mortality in men. The National Osteoporosis Foundation recommends fracture risk assessment with the online WHO/FRAX tool. Although androgen deprivation therapy for prostate cancer increases fracture risk, there is limited information about which men require preventative drug therapy. We applied the WHO/FRAX tool to men treated with androgen deprivation therapy for prostate cancer.


METHODS
Information was collected from a practice cohort of men treated with gonadotropin-releasing hormone agonists, and included age, height, weight, history of gonadotropin-releasing hormone agonist treatment, dual energy x-ray absorptiometry results, prior bone targeted therapy and clinical risk factors for fracture. Subjects were evaluated with the WHO/FRAX algorithm (http://www.shef.ac.uk/FRAX/).


RESULTS
A total of 363 men treated with androgen deprivation therapy (median age 72 years) were evaluated. By the FRAX algorithm with clinical information (no dual energy x-ray absorptiometry data) the 3% hip fracture risk threshold for treatment was exceeded by 51.2% of the men (median risk 3.1%). When subjects were grouped by age the treatment threshold was reached by 3.3% of those younger than 70 years, 76.6% of those 70 to 79 years old and by 98.8% of those 80 years old or older. Using FRAX with bone mineral density data in the 93 patients who underwent bone mineral density testing the median 10-year hip fracture risk was 0.9% and the treatment threshold was exceeded by 15% of these subjects.


CONCLUSIONS
In this cohort of men receiving androgen deprivation therapy the prevalence of risk sufficient to necessitate drug therapy was high and was strongly influenced by age. The WHO/FRAX algorithm identifies a greater proportion of men for treatment than the traditional threshold of T score -2.5 or less.
Saylor
Philip J
PJ
Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. psaylor@partners.org
Kaufman
Donald S
DS
Michaelson
M Dror
MD
Lee
Richard J
RJ
Smith
Matthew R
MR
D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000726:Androgen Antagonists / Q000009:adverse effects*; D050723:Fractures, Bone / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
12359855
Osteoporos Int. 2005 Jul;16(7):737-42
15455194
Osteoporos Int. 1997;7(5):407-13
9425497
J Urol. 1999 Apr;161(4):1219-22
10081873
J Bone Miner Res. 2005 Jul;20(7):1185-94
15940371
J Clin Endocrinol Metab. 1999 Oct;84(10):3431-4
10522975
J Urol. 2000 Jan;163(1):181-6
10604342
Osteoporos Int. 2005 Nov;16(11):1330-8
15928804
J Bone Miner Res. 2004 Jun;19(6):893-9
15125788
J Bone Miner Res. 2005 Mar;20(3):494-500
15746995
Osteoporos Int. 2006;17(11):1577-83
16896511
N Engl J Med. 2005 Jan 13;352(2):154-64
15647578
J Clin Oncol. 2003 Aug 15;21(16):3150-7
12915606
J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
11836291
Osteoporos Int. 2008 Apr;19(4):385-97
18292978
Osteoporos Int. 2005 Feb;16(2):155-62
15175845
World Health Organ Tech Rep Ser. 1994;843:1-129
7941614
Osteoporos Int. 2008 Apr;19(4):449-58
18292975
Bone. 2004 Nov;35(5):1029-37
15542027
J Urol. 2006 Jan;175(1):136-9; discussion 139
16406890
Osteoporos Int. 2010 Apr;21(4):647-53
19533207
J Clin Oncol. 2005 Nov 1;23(31):7897-903
16258089
J Clin Densitom. 2008 Oct-Dec;11(4):473-7
18562228
J Bone Miner Metab. 2003;21(1):17-21
12491089
Bone. 2004 Aug;35(2):375-82
15268886
J Urol. 2002 Jun;167(6):2361-7; discussion 2367
11992038
N Engl J Med. 2001 Sep 27;345(13):948-55
11575286
Osteoporos Int. 2005 Jun;16(6):581-9
15616758